Pneumococcal Vaccine Clinical Trial
Official title:
Assessment of Knowledge, Facilitators and Barriers of Pneumococcal Vaccination: A Cross-sectional Study Among Diabetologists in India
| Verified date | March 2024 |
| Source | M.V. Hospital for Diabetes |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Asia has the highest burden with the largest contribution of pneumonia burden from India. Pneumonia is also observed as 5th leading cause of deaths in India. People with diabetes with uncontrolled glucose are significantly at higher risk of development of pneumonia. Even though, pneumonia is a vaccine-preventable disease, hospitalization for pneumonia of patients with diabetes are rising. Very limited literature is available on the knowledge and practice of pneumonia vaccination among diabetologists and the rate of pneumonia vaccination received by the patients with diabetes. Hence this study aims to assess their knowledge on the same. In addition, this study also aims to identify the real barriers and facilitators of pneumococcal vaccination among diabetologists in India. A cross-sectional study will be conducted among 25diabetologists in each of the four zones in India representing all directions - North, East, West and South. Diabetologists will be selected through purposive sampling. A semi-structured questionnaire (study tool) is designed based on the existing literature that addresses our objectives. An education session on Pneumococcal vaccination will be conducted for the diabetologists through webinar after completing the survey. A post assessment will be done using the same questionnaire among the study participants after the education session in order to see an increase in the knowledge of pneumococcal vaccination.
| Status | Completed |
| Enrollment | 100 |
| Est. completion date | March 22, 2024 |
| Est. primary completion date | March 22, 2024 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 25 Years to 65 Years |
| Eligibility | Inclusion Criteria: Diabetologists willing to participate in the study Exclusion Criteria: Unwillingness to give consent for participation |
| Country | Name | City | State |
|---|---|---|---|
| India | M V Hospital for Diabetes [P] Limited | Chennai | Tamil Nadu |
| Lead Sponsor | Collaborator |
|---|---|
| M.V. Hospital for Diabetes | MSD Pharmaceuticals LLC |
India,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | To identify the facilitators and barriers of pneumococcal vaccination among diabetologists in India. | 6 months | ||
| Secondary | To assess the knowledge, attitude and practices of pneumococcal vaccination among select diabetologists across India. | 6 months | ||
| Secondary | To examine the association of knowledge and practice of vaccination among diabetologists | 6 months | ||
| Secondary | To assess the change in the knowledge of pneumococcal vaccination post educational intervention | 6 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01521897 -
Prevenar Special Use-result Surveillance in Japan (Regulatory PostMarketing Commitment Plan)
|
N/A | |
| Completed |
NCT03098628 -
Trial of Simplified Pneumococcal Vaccination in Vietnam II
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT06337643 -
A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine
|
Phase 1 | |
| Recruiting |
NCT03046134 -
Burden of Hospitalized Pneumonia in Korea COPD Population
|
N/A | |
| Completed |
NCT00689351 -
Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered To Infants In Korea
|
Phase 2 | |
| Recruiting |
NCT06181656 -
Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation
|
||
| Completed |
NCT05788510 -
Pneumococcal Vaccination in Patients With Anti-TNF Alpha Therapy
|